TEM (Tempus AI, Inc.) — AI Stock Analysis & Recommendation

Research of October 13, 2026 · Healthcare / Services-Computer Programming, Data Processing, Etc.

TradeFlare's AI research teams rate TEM a HOLD. The latest price is $68.22.

The research plan

• Entry: $68.22
• Target: $78.45
• Stop: $57.99
• Time horizon: weeks

The stock is exhibiting a neutral technical setup with high volatility, suggesting a need for further price action confirmation before a confident entry.

Why

The stock is exhibiting a neutral technical setup with high volatility, suggesting a need for further price action confirmation before a confident entry. Catalysts to watch: Continued positive news flow from deal announcements and FDA clearances; Analyst sentiment remains generally positive, which could provide underlying support; Potential for a mean-reversion bounce from oversold RSI levels. Key risks: High realized volatility and significant drawdown history, indicating potential for sharp price swings; Persistent unprofitability and negative cash flow, raising concerns about long-term financial health; High debt-to-equity ratio amplifies financial risk.

What could push TEM higher

• Continued positive news flow from deal announcements and FDA clearances.
• Analyst sentiment remains generally positive, which could provide underlying support.
• Potential for a mean-reversion bounce from oversold RSI levels.

Key risks for TEM

• High realized volatility and significant drawdown history, indicating potential for sharp price swings.
• Persistent unprofitability and negative cash flow, raising concerns about long-term financial health.
• High debt-to-equity ratio amplifies financial risk.

What each AI research team found

Fundamental team: Neutral · valuation: speculative

Tempus AI demonstrates strong revenue growth and a significant competitive advantage through its data moat, but its current unprofitability and high leverage present considerable risks. The neutral verdict reflects the speculative nature of the valuation, balancing growth potential against financial health concerns, with the analyst consensus providing a potential upside target.

• Strong revenue growth (21.6% YoY) and healthy gross margins (63.98%) indicate market traction and pricing power.
• Significant unprofitability with negative net and operating margins, coupled with negative operating and free cash flow, highlight a substantial cash burn.
• A high debt-to-equity ratio (3.25) indicates significant financial leverage.

Technical team: Neutral

The analysis presents a mixed picture with a bullish pattern on the daily chart countered by neutral signals from trend and volume analysis. The stock is currently trading near resistance, and the lack of clear directional momentum or volume confirmation warrants a neutral stance until a decisive move occurs.

• The price is consolidating near a resistance level, with short-term bullish momentum but overall uncertainty due to lack of long-term trend indicators.
• The stock is trading in a sideways range with mixed volume signals, suggesting a neutral outlook until a clear breakout or breakdown occurs.
• Momentum indicators are neutral, with no strong signals for a bullish or bearish move, suggesting a sideways trend.

Sentiment team: Neutral

The sentiment for TEM is currently neutral, reflecting a balance between positive news regarding partnerships and FDA clearances, and persistent concerns about profitability and valuation. While analyst sentiment leans positive, this is tempered by the inherent risks of a pre-revenue biotech and mixed analyst ratings, leading to a stable but not strongly trending sentiment.

• Tempus AI (TEM) news coverage is predominantly neutral, with a slight positive lean due to recent deal announcements and price target raises, but tempered by ongoing negative earnings estimates and the inherent risks of a pre-revenue biotech company. (Score: 0.042)
• Tempus AI (TEM) exhibits a neutral sentiment driven by a mix of positive developments like FDA clearance and analyst price target increases, countered by ongoing concerns regarding profitability and cash burn, with retail investor sentiment reflecting this...
• Tempus AI (TEM) exhibits a generally positive analyst sentiment driven by strong institutional backing, strategic partnerships, and pipeline developments, though concerns regarding profitability and valuation persist. (Consensus: POSITIVE)

Risk team: High

TEM presents a high-risk profile due to its extreme volatility, significant historical drawdowns, and concerning fundamental metrics including negative profitability and cash flow, coupled with high leverage. The frequent large price gaps and high short interest further exacerbate these risks, necessitating a very cautious approach.

• High Realized Volatility and Drawdown: The stock exhibits extremely high realized volatility (over 90% annualized) and a significant 1-year maximum drawdown of nearly 60%, indicating substantial price swings and potential for large losses.
• Negative Profitability and Cash Flow: The company consistently generates negative net income, operating income, and free cash flow, raising concerns about its long-term viability and reliance on external financing.
• High Leverage: A high debt-to-equity ratio indicates significant financial leverage, making the company more vulnerable to interest rate fluctuations and economic downturns.

TEM at a glance

Market value	$12.6M
Revenue growth (year over year)	50.4%
Profit margin	-17.8%
Debt / equity	0.00

Every AI call on TEM since July 21, 2026, and what happened next (10 calls) →

Research of October 13, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.